NORTHBROOK, Ill. (AP) – Arthritis-treatment developer Horizon Pharma Inc. said that the Food and Drug Administration has accepted its application for the rheumatoid arthritis treatment Lodotra and plans to make a decision on the drug by July 26.
Lodotra is a low-dose form of the steroid prednisone, and it is designed to reduce stiffness associated with rheumatoid arthritis.
Horizon Pharma, based in Northbrook, Ill., said Lodotra is currently approved for marketing in 16 European companies.
Earlier this year, the company completed an initial public offering of stock that raised $49.5 million.
Date: November 29, 2011
Source: Associated Press
